Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

被引:42
作者
Chebib, Nader [1 ]
Mornex, Jean-Francois [1 ,2 ]
Traclet, Julie [1 ]
Philit, Francois [1 ]
Khouatra, Chahera [1 ]
Zeghmar, Sabrina [1 ]
Turquier, Segolene [1 ]
Cottin, Vincent [1 ,2 ]
机构
[1] Hosp Civils Lyon, Natl Reference Ctr Rare Pulm Dis, Competence Ctr Severe Pulm Hypertens, Lyon, France
[2] Claude Bernard Lyon 1 Univ, Univ Lyon, Lyon, France
关键词
emphysema; interstitial lung disease; pulmonary hypertension; ARTERIAL-HYPERTENSION; CONTROLLED-TRIAL; HEART-FAILURE; SILDENAFIL; PREVALENCE; OUTCOMES; FIBROSIS; SURVIVAL; FRANCE; TRENDS;
D O I
10.1177/2045894018775056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age.
引用
收藏
页数:10
相关论文
共 35 条
[1]   Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease [J].
Andersen, Kasper Hasseriis ;
Iversen, Martin ;
Kjaergaard, Jesper ;
Mortensen, Jann ;
Nielsen-Kudsk, Jens Erik ;
Bendstrup, Elisabeth ;
Videbaek, Regitze ;
Carlsen, Jorn .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04) :373-380
[2]   Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry [J].
Badesch, David B. ;
Raskob, Gary E. ;
Elliott, C. Greg ;
Krichman, Abby M. ;
Farber, Harrison W. ;
Frost, Adaani E. ;
Barst, Robyn. J. ;
Benza, Raymond L. ;
Liou, Theodore G. ;
Turner, Michelle ;
Giles, Scott ;
Feldkircher, Kathy ;
Miller, Dave P. ;
McGoon, Michael D. .
CHEST, 2010, 137 (02) :376-387
[3]   Aging in France: Population Trends, Policy Issues, and Research Institutions [J].
Beland, Daniel ;
Durandal, Jean-Philippe Viriot .
GERONTOLOGIST, 2013, 53 (02) :191-197
[4]   Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial [J].
Blanco, Isabel ;
Santos, Salud ;
Gea, Joaqim ;
Gueell, Rosa ;
Torres, Ferran ;
Gimeno-Santos, Elena ;
Rodriguez, Diego A. ;
Vilaro, Jordi ;
Gomez, Begona ;
Roca, Josep ;
Albert Barbera, Joan .
EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (04) :982-992
[5]   Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension [J].
Blanco, Isabel ;
Gimeno, Elena ;
Munoz, Phillip A. ;
Pizarro, Sandra ;
Gistau, Concepcion ;
Rodriguez-Roisin, Robert ;
Roca, Josep ;
Albert Barbera, Joan .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (03) :270-278
[6]   Severe pulmonary hypertension in lung disease: phenotypes and response to treatment [J].
Brewis, Melanie J. ;
Church, Alistair C. ;
Johnson, Martin K. ;
Peacock, Andrew J. .
EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (05) :1378-1389
[7]   Severe pulmonary hypertension and chronic obstructive pulmonary disease [J].
Chaouat, A ;
Bugnet, AS ;
Kadaoui, N ;
Schott, R ;
Enache, I ;
Ducoloné, A ;
Ehrhart, M ;
Kessler, R ;
Weitzenblum, E .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (02) :189-194
[8]   Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome [J].
Cottin, V. ;
Le Pavec, J. ;
Prevot, G. ;
Mal, H. ;
Humbert, M. ;
Simonneau, G. ;
Cordier, J-F. .
EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (01) :105-111
[9]   Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure - A report from the OPTIMIZE-HF registry [J].
Fonarow, Gregg C. ;
Stough, Wendy Gattis ;
Abraham, William T. ;
Albert, Nancy M. ;
Gheorghiade, Mihai ;
Greenberg, Barry H. ;
O'Connor, Christopher M. ;
Sun, Jie Lena ;
Yancy, Clyde W. ;
Young, James B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (08) :768-777
[10]   The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States How REVEAL Differs From Historic and Non-US Contemporary Registries [J].
Frost, Adaani E. ;
Badesch, David B. ;
Barst, Robyn J. ;
Benza, Raymond L. ;
Elliott, Gregory ;
Farber, Harrison W. ;
Krichman, Abby ;
Liou, Theodore G. ;
Raskob, Gary E. ;
Wason, Prieya ;
Feldkircher, Kathleen ;
Turner, Michelle ;
McGoon, Michael D. .
CHEST, 2011, 139 (01) :128-137